ACURASTEM INC
UNC13A antisense oligonucleotide therapy targeting cryptic exon inclusion to restore protein function in ALS and FTD
- Sector
- Biotech
- Headquarters
- MONROVIA, CA
- Founded
- 2016
- Latest Form D
- $5M offered, Jun 2026
- Total capital
- $15.9M
- Federal grants
- $12.3M
- 15 awards · 2017–2024
- Rank in peer group#305 of 392
- Private capital raised
- $3.6M
- 4 Form D · last Jun 2026
- 4 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 11 pending · first 2024
- Rank in peer group#70 of 392
Capital timeline
Latest events
- Offering registeredForm D · SEC · 4th filing$5M
- Federal grantHealth and Human S · Phase II · Development of an UNC13A antisense oligonucleotide treatment for ALS and FTD$1.3M
- Federal grantHealth and Human S · Phase II · Development of a SYF2 antisense oligonucleotide treatment for ALS and FTD$1.4M
- Federal grantHealth and Human S · Phase II · Development of an UNC13A antisense oligonucleotide treatment for ALS and FTD$1.4M
- Federal grantHealth and Human S · Phase II · Development of a SYF2 antisense oligonucleotide treatment for ALS and FTD$1.5M
- Private capital raisedForm D · SEC · 3rd filing$3.1M
- Private capital raisedForm D · SEC · 2nd filing$400K
- Private capital raisedForm D · SEC · 1st filing$50K
Show 11 earlier federal awards
- Federal grantHealth and Human S · Phase II · Development of a PIKFYVE antisense oligonucleotide treatment for FTD$76K
- Federal grantHealth and Human S · Phase II · Development of a PIKFYVE Antisense Oligonucleotide Treatment for FTD$41K
- Federal grantHealth and Human S · Phase II · Development of a PIKFYVE antisense oligonucleotide treatment for FTD$1.5M
- Federal grantHealth and Human S · Phase II · Development of a PIKFYVE antisense oligonucleotide treatment for FTD$1M
- Federal grantHealth and Human S · Phase II · PIKFYVE antagonism as a therapy for C9ORF72-ALS/FTD$533K
- Federal grantHealth and Human S · Phase II · PIKFYVE antagonism as a therapy for C9ORF72-ALS/FTD$1.1M
- Federal grantHealth and Human S · Phase II · PIKFYVE antagonism as a therapy for C9ORF72-ALS/FTD$1.3M
- Federal grantHealth and Human S · Phase II · PIKFYVE antagonism as a therapy for C9ORF72-ALS/FTD$265K
- Federal grantHealth and Human S · Phase II · PIKFYVE antagonism as a therapy for C9ORF72-ALS/FTD$433K
- Federal grantHealth and Human S · Phase I · Preserving cellular aspects of aging in patient specific models of ALS$225K
- Federal grantHealth and Human S · Phase I · Preserving cellular aspects of aging in patient-specific models of ALS$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
10months
from ACURASTEM INC’s first federal award to its first private round.
- First federal award · Sep 2017
- Health and Human S · $225K
- First Form D · Jul 2018
- $50K · 1st Form D
- Awards before first raise
- 3 awards
An association in public records, not a cause or a prediction.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#70 · top 18%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Samuel AlworthResearcherExecutive Officer, DirectorLinked by $9.4M in grants as PI
- Justin IchidaExecutive Officer, DirectorNamed in SEC Form D filings
- Marcel van der BrugExecutive OfficerNamed in SEC Form D filings
- Paul AugustDirectorNamed in SEC Form D filings
- Qing Liu-MichaelDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 12- GrantedUNC13A Antisense OligonucleotidesUSPTOUS 12,104,155
- PendingTreatment Of Viral Infections With Combination Of Pikfyve Kinase Inhibitors And TMPRSS-2 InhibitorsUSPTOApplication 17302438
- PendingPikfyve Kinase InhibitorsUSPTOApplication 16641159
Show all 12 patent records
- UNC13A Antisense OligonucleotidesOct 1, 2024 · US 12,104,155Granted
- Treatment Of Viral Infections With Combination Of Pikfyve Kinase Inhibitors And TMPRSS-2 InhibitorsNov 4, 2021 · Application 17302438Pending
- Pikfyve Kinase InhibitorsJun 25, 2020 · Application 16641159Pending
- UNC13A Antisense OligonucleotidesApplication PCTUS2022037888Pending
- Pikfyve Antisense OligonucleotidesApplication PCTUS2022034539Pending
- UNC13A Antisense OligonucleotidesApplication 63364830Pending
- UNC13A Antisense OligonucleotidesApplication 63203409Pending
- Pikfyve Antisense OligonucleotidesApplication 63202717Pending
- SYF2 Antisense OligonucleotidesApplication 63513063Pending
- Pikfyve InhibitorsApplication PCTUS2018048369Pending
- SYF2 Antisense OligonucleotidesApplication 63482514Pending
- UNC13A Antisense OligonucleotidesApplication 63480704Pending
Related companies, and why
- SENSORIUM THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
- EVINCIS BIO, INC.Similar federal contract value in Biotech · null in contracts
- VITRISTOR LLCSimilar federal contract value in Biotech · null in contracts
- CYTOTERRA INC.Similar federal contract value in Biotech · null in contracts
- MECHASIM INC.Similar federal contract value in Biotech · null in contracts
- ASP Isotopes Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .